BBOT

1.8102.69%
FP

Frank P. McCormick

Chairman of Scientific Advisory Board

Dr. Frank P. McCormick, Ph.D. F.R.S. D.Sc. (Hon)., is Co-Founder of BridgeBio Oncology Therapeutics, Inc. and was its Independent Chairman and serves as its Chair. He Advisory Board and Non-Executive Director since May 2024 to December 2025. He has served as a member of our board of directors since April 2024 and was previously a member of our board of directors from August 2016 to November 2016 He is Medical & Scientific Advisors and Member Of Advisory Board of DiaCarta, Inc. He serves as Member of Scientific Advisory Board of U.S. Caris MPI, Inc. (d/b/a Caris Life Sciences, Inc.) He is Co-Founder of BridgeBio Pharma, Inc and has been its Chairman of Oncology since April 2019 and serves as its Director since February 21, 2023. He is Member of Scientific Advisory Board at Vilya, Inc. He serves as Member of Scientific Advisory Board of Research Trends & Emerging Technologies at Amgen Inc. He was Member of Scientific Advisory Board of PMV Pharmaceuticals, Inc. until 2024. He had been Scientific Founder of Avidity Biosciences LLC since 2012. He serves as a Member of Scientific Advisory Board at Quanta Therapeutics, Inc and Quadriga BioSciences, Inc. He is a Director of EXUMA Biotech Corp. since its joining in February 2020. He served as Member of Scientific Advisory Board at Biosplice Therapeutics, Inc until 2025. He serves as Member of Scientific Advisory Board at IconOVir Bio, Inc. since April 2021. He serves as Chairman of Scientific Advisory Board at Olema Oncology, Inc. (formerly known as Olema Pharmaceuticals, Inc.) since April 2021. He serves as Member of Scientific & Clinical Advisory Board ay Apollomics, Inc since August 02, 2017. He serves as Member of Scientific Advisory Board & Director of Remedy Plan, Inc. He is Member of Scientific Advisory Board of IDEAYA Biosciences, Inc. since February 13, 2019 and serves as Chair of. He IDEAYA Scientific Advisory Board from January 2022. He serves as a Scientific Advisor of Kura Oncology, Inc. He has been a Scientific Founder of Avidity NanoMedicines LLC since 2012. He serves as an Ad-Hoc Advisor of PrognosDx Health, Inc. He served as an Advisor at Aglaia Oncology Fund (formerly known as AGLAIA BioMedical Ventures B.V.). He is a Co-Founder of DNAtriX, Inc. He served as Member of Scientific Advisory Board at Frontier Medicines Corporation since July 2021 until 2025. He serves as a Scientific Advisor at Onyx Pharmaceuticals, Inc. Exelixis Inc. He Jackson Laboratory. He National Cancer Institute and Massachusetts General Hospital, Lawrence. He has been a Senior Advisor of Research and Development Organization, since October 30, 2003. He has been an Associate Dean of School of Medicine of UCSF, since 1997. He founded Onyx Pharmaceuticals in 1992 and served as. He Chief Scientific Officer from 1992 to 1996. He served as a Medical Advisor at DNA Direct, Inc. He served as a Vice President of Therapeutic Research at Chiron, Corp. from 1991 to 1992. He served as a Vice President of Discovery Research at Cetus Oncology Corporation from 1981 to 1990, Director of Molecular Biology from 1981 to 1990 and Vice President of Research from 1990 to 1991. He serves as Chairman of Scientific Advisory Board of Kyras Therapeutics Inc. He has been. He David A. Wood Chair of Tumor Biology and Cancer Research in. He Department of Microbiology and Immunology at University of California since 1998. He served as. He President of. He Board of Directors of American Association for Cancer Research (AACR) from April 2, 2012 to April 2013 and has a leadership role at. He Frederick National Lab for Cancer Research. He served as. He Chairman and Member of. He Scientific Advisory Board at NexGenix Pharmaceuticals Holdings, Inc. He serves as a Director of. He University of California, San Francisco (UCSF) Helen Diller Comprehensive Cancer Center. He serves as a Director of Onyx Pharmaceuticals, Inc. He served as a Director of DNAtriX, Inc. until January 2021. He serves as a Member of Advisory Board of DiaCarta Inc. He served as a Director of Aduro BioTech, Inc. from 2010 to February 19, 2019 and serves as its Member of Scientific Advisory Board. He serves as a Member of Scientific Advisory Board and Member of Board of Managers at Avidity Biosciences, Inc. (formerly known as Avidity Biosciences LLC). He served as a Member of Scientific Advisory Board of Pancreatic Cancer Action Network, Inc. He serves as a Director and Member of Scientific & Clinical Advisory Board at BiPar Sciences, Inc. He serves as Member of Scientific Advisory Board of Portola Pharmaceuticals, Inc. SillaJen Biotherapeutics, Inc. ORCA Therapeutics B.V., Iconix Pharmaceuticals, Inc. Sagres Discovery, Inc. and KineMatik Ltd. He has been a Member of Scientific Advisory Board of Dicerna Pharmaceuticals, Inc. since October 2008. He has been Member of Advisory Board at Standard BioTools Inc. (formerly known as Fluidigm Corporation) since December 11, 2006. He served as Member of Scientific Advisory Board of Innovent Biologics, Inc. and Caris Life Sciences, Inc. He serves as a Member of. He UCSF Biomedical Sciences Program and. He Herbert Boyer Program in Biological Sciences. He is on. He Advisory Boards of Memorial Sloane Kettering, Dana Farber Cancer Center. He Canary Foundation. He University of Wisconsin Comprehensive Cancer Center and. He University of Texas, Southwestern Advisory Board. He serves on. He Editorial Board of some of. He most prestigious international cancer publications and serves as a Board Member or Advisor to multiple cancer research organizations. He served as a Member of Scientific Advisory Board at OncoCyte Corporation. He served as a Member of Scientific Advisory Board of Aglaia Oncology Fund (formerly known as AGLAIA BioMedical Ventures B.V.). He served as a Member of Scientific Advisory Board at Iconix Biosciences, Inc. He served as a Director of American Association For Cancer Research. He served as a Director of Exelixis, Inc. from July 31, 2003 to May 28, 2014 and served as its Member of. He Scientific Advisory Board. He served as a Director of UCSF Helen Diller Comprehensive Cancer Center from March 17, 2014 to December 31, 2014. He serves as a Professor of Tumor Biology and Cancer Research, Department of Microbiology and Immunology at University of California-San Francisco. He is an Emiritus Professor of. He University of California, San Francisco. He is Professor Emeritus of. He UCSF Helen Diller Comprehensive Cancer Center. He is. He E. Dixon Heise distinguished Professor in Oncology. He serves as RAS National Program Advisor and Member of. He National Academy of Sciences. He has been a Fellow of. He Royal Society, since 1996. He was a Post-Doctoral Fellow with Dr. Allen Smith at. He Imperial Cancer Research Fund in London, England and with Professor Seymour S. Cohen at. He State University of New York at Stony Brook. He holds. He David A. Wood Chairman of Tumor Biology and Cancer Research in UCSF's Department of Microbiology and Immunology. He is an expert on

Positions